Next-Generation Imaging

Latest News

FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer
FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer

August 10th 2025

The target action date for the application is March 6, 2026.

3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

July 18th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

July 15th 2025

Trial launches of diagnostic agent for clear cell renal cell carcinoma
Trial launches of diagnostic agent for clear cell renal cell carcinoma

June 23rd 2025

FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting
FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting

June 23rd 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.